Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Mortgage Rates And Demand Are Stuck In A Holding Pattern
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
NEW BRUNSWICK, N.J., May 23, 2024 ~ At the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will be leading sessions and presenting their latest discoveries from their innovative cancer research program. The meeting, which will be held in Chicago from May 30-June 4, will feature a total of 49 accepted abstracts and presentations covering cutting-edge topics in the field of oncology.
The team at Rutgers Cancer Institute and RWJBarnabas Health is renowned for their integrated network of researchers and clinicians who are dedicated to finding strategies that will achieve the best possible outcomes for cancer patients. According to Steven K. Libutti, MD, FACS, Director of Rutgers Cancer Institute and Senior Vice President of Oncology Services at RWJBarnabas Health, the dynamic lineup of presentations at this year's ASCO Annual Meeting reflects their commitment and dedication to advancing cancer research and care.
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state, Rutgers Cancer Institute and RWJBarnabas Health are at the forefront of conquering a disease that impacts so many. They are eager to share their recent advancements and findings with the wider oncology community at this year's meeting.
More on illi News
The research accepted for presentation at ASCO includes one late-breaking abstract, as well as oral and poster sessions featuring data on various types of cancer such as breast, colorectal, lymphoma, and lung. One study that will be highlighted at the meeting examines how social vulnerability affects clinical trial enrollment among patients with breast, prostate, lung, colorectal or pancreatic cancer. The findings confirm that neighborhood social vulnerability is a barrier to trial enrollment, particularly among Black patients.
Another study focuses on enhanced recovery after surgery (ERAS) protocols for radical cystectomy. This study reviewed data from over 3,700 patients who underwent radical cystectomy and found that increased compliance with ERAS components was associated with improved postoperative recovery and shorter hospital stays.
Updates from a Phase 1/1b study investigating the AKT inhibitor ipatasertib in combination with chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) will also be presented. This study aims to determine the maximum tolerated dose of ipatasertib in combination with definitive chemoradiation therapy for HNSCC.
More on illi News
Additionally, data from a Phase 3 clinical trial evaluating the efficacy and safety of odronextamab plus CHOP versus rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients will be shared. The study, known as OLYMPIA-3, is comparing the two treatment regimens in patients with intermediate- or high-risk features of DLBCL.
Another interesting presentation will focus on a single institution pilot study, CIPHER, which evaluated whether circulating tumor DNA (ctDNA) testing during neoadjuvant therapy can serve as an early indicator of treatment response and inform disease management in the adjuvant setting. The study included 35 patients with stage II-III triple negative and HER2+ breast cancer who underwent longitudinal ctDNA testing during standard of care neoadjuvant therapy.
The full list of presentations at this year's ASCO Annual Meeting can be found on their website. With such a diverse range of topics being covered by Rutgers Cancer Institute and RWJBarnabas Health, it is clear that they are making significant contributions to the field of oncology and are dedicated to improving outcomes for cancer patients.
The team at Rutgers Cancer Institute and RWJBarnabas Health is renowned for their integrated network of researchers and clinicians who are dedicated to finding strategies that will achieve the best possible outcomes for cancer patients. According to Steven K. Libutti, MD, FACS, Director of Rutgers Cancer Institute and Senior Vice President of Oncology Services at RWJBarnabas Health, the dynamic lineup of presentations at this year's ASCO Annual Meeting reflects their commitment and dedication to advancing cancer research and care.
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state, Rutgers Cancer Institute and RWJBarnabas Health are at the forefront of conquering a disease that impacts so many. They are eager to share their recent advancements and findings with the wider oncology community at this year's meeting.
More on illi News
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
The research accepted for presentation at ASCO includes one late-breaking abstract, as well as oral and poster sessions featuring data on various types of cancer such as breast, colorectal, lymphoma, and lung. One study that will be highlighted at the meeting examines how social vulnerability affects clinical trial enrollment among patients with breast, prostate, lung, colorectal or pancreatic cancer. The findings confirm that neighborhood social vulnerability is a barrier to trial enrollment, particularly among Black patients.
Another study focuses on enhanced recovery after surgery (ERAS) protocols for radical cystectomy. This study reviewed data from over 3,700 patients who underwent radical cystectomy and found that increased compliance with ERAS components was associated with improved postoperative recovery and shorter hospital stays.
Updates from a Phase 1/1b study investigating the AKT inhibitor ipatasertib in combination with chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) will also be presented. This study aims to determine the maximum tolerated dose of ipatasertib in combination with definitive chemoradiation therapy for HNSCC.
More on illi News
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
Additionally, data from a Phase 3 clinical trial evaluating the efficacy and safety of odronextamab plus CHOP versus rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients will be shared. The study, known as OLYMPIA-3, is comparing the two treatment regimens in patients with intermediate- or high-risk features of DLBCL.
Another interesting presentation will focus on a single institution pilot study, CIPHER, which evaluated whether circulating tumor DNA (ctDNA) testing during neoadjuvant therapy can serve as an early indicator of treatment response and inform disease management in the adjuvant setting. The study included 35 patients with stage II-III triple negative and HER2+ breast cancer who underwent longitudinal ctDNA testing during standard of care neoadjuvant therapy.
The full list of presentations at this year's ASCO Annual Meeting can be found on their website. With such a diverse range of topics being covered by Rutgers Cancer Institute and RWJBarnabas Health, it is clear that they are making significant contributions to the field of oncology and are dedicated to improving outcomes for cancer patients.
Filed Under: Business
0 Comments
Latest on illi News
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Mt. Carmel's Claude Mpouma to Announce College Commitment — Media Invited
- Bennett Awards Crafts Custom Trophies for Inaugural OMTEC Awards at 2025 Orthopedic Expo
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- The Lashe Rapid Dry Adhesive & Fan Lash Extensions Featured in eWellness Magazine's Lash Story
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- Chicago: Mayor Brandon Johnson Announces 2026 Budget Engagement Roundtables
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Universal Destinations & Experiences Plans Second Universal Horror Unleashed in Chicago
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Big Green Egg and Ace Hardware Launch "Egg Your Neighbor" Contest to Celebrate Neighborhood Heroes
- Pi9 Becomes a Microsoft Training Services Partner